Comparing granulocyte colony–stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients-Reference-Cited by-同舟云学术

Comparing granulocyte colony–stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients

Published:2018-01 Issue: Volume:89 Page:49-55
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Botteri Edoardo,Krendyukov Andriy,Curigliano Giuseppe

Funder

CSF

Sandoz GmbH, Kundl, Austria

Spirit Medical Communications Ltd.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference38 articles.

1. Recommendations for the use of WBC growth factors: American Society of clinical oncology clinical practice guideline update;Smith;J Clin Oncol,2015

2. Myeloid growth factors. Clinical practice guidelines in oncology;Crawford;J Natl Compr Canc Netw,2007

3. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours;Aapro;Eur J Cancer,2011

4. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications;Crawford;Ann Oncol,2010

5. Canadian supportive care recommendations for the management of neutropenia in patients with cancer;Kouroukis;Curr Oncol,2008

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Recent Overview of the Growing Applications of Biosimilars in Pancreatic Cancer Management: Current Picture and Future Perspectives;Biosimilars for Cancer Treatment;2024

2. Achieving white blood cell equity: are the safety profiles of biosimilar and reference pegfilgrastims comparable?;Future Oncology;2023-08-23

3. Safety profile of G-CSF in chemotherapy-induced neutropenia;Indian Journal of Cancer;2022-10

4. Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis;Frontiers in Pharmacology;2022-07-05

5. Comparative study on the effects of filgrastim and pegfilgrastim in the treatment of fever and neutropenia in patients with leukemia in the west of Iran;Iranian Journal of Pediatric Hematology & Oncology;2022-03-30